El-Amm, Joelle; Patel, Nihar; Freeman, Ashley; Aragon-Ching, Jeanny B.
(2017-09-22)
Enzalutamide, previously known as MDV300, is an oral, second-generation androgen receptor (AR) signaling inhibitor or antagonist that was approved by the Food and Drug Administration in 2012 for the treatment of metastatic ...